Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.

Silva JM, Deuker MM, Baguley BC, McMahon M.

Pigment Cell Melanoma Res. 2017 May;30(3):353-367. doi: 10.1111/pcmr.12586. Epub 2017 Apr 20.

2.

Rational targeting of BRAF and PI3-Kinase signaling for melanoma therapy.

Deuker MM, McMahon M.

Mol Cell Oncol. 2015 May 7;3(3):e1033095. doi: 10.1080/23723556.2015.1033095. eCollection 2016 May.

3.

PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.

Deuker MM, Marsh Durban V, Phillips WA, McMahon M.

Cancer Discov. 2015 Feb;5(2):143-53. doi: 10.1158/2159-8290.CD-14-0856. Epub 2014 Dec 3.

4.

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.

Holderfield M, Deuker MM, McCormick F, McMahon M.

Nat Rev Cancer. 2014 Jul;14(7):455-67. doi: 10.1038/nrc3760. Review.

5.

Cancer biology: Enzyme meets a surprise target.

Deuker MM, McMahon M.

Nature. 2014 Jun 12;510(7504):225-6. doi: 10.1038/nature13343. Epub 2014 May 21. No abstract available.

6.

Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.

Marsh Durban V, Deuker MM, Bosenberg MW, Phillips W, McMahon M.

J Clin Invest. 2013 Dec;123(12):5104-18. doi: 10.1172/JCI69619. Epub 2013 Nov 8.

Supplemental Content

Loading ...
Support Center